(Q48513543)

12 February 2018

title

Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. (English)

1 reference

12 February 2018

author

Felix Chun

5

1 reference

12 February 2018

Alberto Briganti

6

Alberto Briganti

1 reference

12 February 2018

10

Pierre I Karakiewicz

1 reference

12 February 2018

Markus Graefen

8

Markus Graefen

1 reference

12 February 2018

Hartwig Huland

9

Hartwig Huland

1 reference

12 February 2018

Francesco Montorsi

7

Francesco Montorsi

1 reference

12 February 2018

Vincenzo Scattoni

3

Vincenzo Scattoni

1 reference

12 February 2018

author name string

Jochen Walz

1

1 reference

12 February 2018

Alexander Haese

2

1 reference

12 February 2018

Thomas Steuber

4

1 reference

12 February 2018

language of work or name

English

0 references

publication date

1 November 2008

1 reference

12 February 2018

number of pages

9

1 reference

inferred from page(s)

published in

Cancer

1 reference

12 February 2018

volume

113

1 reference

12 February 2018

issue

10

1 reference

12 February 2018

page(s)

2695-2703

1 reference

12 February 2018

EAU guidelines on prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Development and external validation of an extended 10-core biopsy nomogram

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Development and external validation of an extended repeat biopsy nomogram

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Methods of calculating prostate-specific antigen velocity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23885

7 January 2021

Identifiers

DOI

10.1002/CNCR.23885

1 reference

12 February 2018

1 reference

12 February 2018